NextPlatNXPL
Recorded

NextPlat 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration24 minParticipants4

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Welcome to the NextPlat Corp third quarter 2026 earnings conference call. Certain statements made during this conference call constitute forward-looking statements. These statements include the capabilities and success of the company's business and any of its products, services, or solutions. The words believe, forecast, project, intend, expect, plan, should, would, and similar expressions, and all statements which are not historical facts are intended to identify forward-looking statements. These forward-looking statements involve and are subject to known and unknown risks, uncertainties, and other factors, any of which could cause the company to not achieve some or all of its goals or the company's previously reported actual results, performance, financial, or operating, including those expressed or implied by such forward-looking statements.

Operator

More detailed information about the company and the risk factors that may affect the realization of forward-looking statements is set forth in the company's filings with the Securities and Exchange Commission, the SEC, copies of which may be obtained from the SEC's website at www.sec.gov. The company assumes no and hereby disclaims any obligation to update the forward-looking statements made during this conference call. Joining us on the call today are David Phipps, Chief Executive Officer, Amanda Ferrio, Chief Financial Officer, and Birute Norkute, Vice President of Healthcare Operations. I will now turn the call over to David Phipps for opening remarks.

David PhippsCEO

Good morning and welcome to NextPlat's third quarter 2026 results conference call. Thank you for joining us. On today's call, as is customary, we will highlight some of the ongoing developments in the business and discuss our continued improvement in our operating results. I will begin today's call by briefly recapping the results of the third quarter, then turn the call over to Birute Norkute, our Vice President of Healthcare Operations, to discuss that segment in more detail, and then to Amanda Ferrio, our Chief Financial Officer, to review our financial results. Following that, I will make closing remarks and then conclude the conference call by responding to questions that were submitted by our shareholders. The third quarter results demonstrate the impact of our efforts to refocus and turn around our business.

David PhippsCEO

As you can clearly see from our year-over-year results, we have generated dramatic improvements across nearly all key financial metrics, most notably in our margins and in the substantial reduction in operating losses. On a sequential basis, while we continue to face some healthcare-related challenges, such as in our existing retail business, which Birute and Amanda will comment on, it is clear that our focus on pursuing higher-margin revenue, like that in our contracted 340B business, is able to generate the types of positive returns we had anticipated. This, combined with our strategy to selectively grow our pharmacy footprint through profitable acquisitions like our recent Scott's Pharmacy purchase, is expected to improve our retail prescription performance. We remain committed to driving both top-line growth and bottom-line profitability in the business, two key factors we believe will generate shareholder value.

David PhippsCEO

At this point, I'd now like to review our business and provide some additional insights, which I believe will add some useful perspective on the developments and trends occurring at NextPlat. In our healthcare segment in the third quarter, our higher-margin contracted healthcare service business continues to deliver increased 340B prescription volumes as newly added contracted customers in this segment complete their onboarding. Quarterly contracted pharmacy revenues increased nearly 300% versus year-ago levels, reflecting the new customers secured in late 2025 and early 2026. On a sequential quarterly basis, however, we did experience a decline in our contracts with medication fulfillment facilities of approximately $0.3 million due to a customer's closure of one of the two facilities we serve, with resultant prescription volume decreases.

David PhippsCEO

Our efforts to profitably expand our business through acquisitions such as Scott's, as well as the continued business development focus on introducing higher-margin services, are expected to offset some of this decline in the near term. As has been the trend, year-over-year total pharmacy prescription revenue was down as anticipated, primarily reflecting lower payer reimbursement rates, prescription volume decreases, and payer mix, all revenue pressures affecting independent retail pharmacies broadly across the industry. This is something Biruta and Amanda will comment on shortly. I would like to note that the addition of our new Scott's Pharmacy in Pensacola, as well as incremental contributions from our recently opened Jacksonville location, are expected to help offset some of these declines going forward. The Scott's operation has been performing well since we purchased it on October the 1st, with margins ahead of our expectations.

David PhippsCEO

Scott's is anticipated to contribute approximately $1.2 million in quarterly revenues and $150,000 in net profits during the fourth quarter, based on current activity levels. We expect revenues, margins, and profitability to grow at Scott's as we roll out new services and seek to secure new contracted clients in the area during 2027. In terms of new contract additions, during the third quarter, we secured three new 340B contracts, bringing the annual total to 14. As we noted previously, the onboarding of 340B entities can take around 90 days on average before initial prescriptions are received, so we're still in the early stages with many of these new clients. We believe each will contribute to growth throughout the remainder of the year and through early 2027.

David PhippsCEO

For the retail pharmacy business, as I noted earlier and last quarter, while there continue to be challenges here, we believe our diversified business model built around well-managed community pharmacies, combined with the addition of our contracted service offerings, will allow us to profitably grow this business. Finally, we continue to focus on actively expanding the scale and scope of our healthcare business through two key pathways. Through the physical offline expansion of our Pharmco Pharmacy footprint, this effort includes adding locations in new markets, such as our acquisition of Scott's in Pensacola and the opening of our new location in Jacksonville. We continue to explore not only additional pharmacy acquisitions, but also new delivery models, such as the automated dispensing at point of care, as we announced recently.

David PhippsCEO

Also online, through the launch of our new e-commerce healthcare website, which will feature an array of popular prescription medications and over-the-counter products, including our Florida Sunshine brand of premium vitamins and supplements. We had originally expected the site to go live before the end of the third quarter, but due to additional time needed to fully optimize the platform for e-commerce at scale, it was delayed slightly, and we now expect the site to go live this month. As a reminder, this new healthcare e-commerce website will allow us to leverage our relationships with current and potential customers as part of our go-to-market plans. Collectively, we believe these initiatives and others we are considering can not only differentiate our services, but also make them attractive to providers while delivering enhanced value to patients. Now turning to our e-commerce segment, here are the most recent highlights.

David PhippsCEO

The global demand for satellite-based connectivity products continues to be strong. In the quarter, we generated sales from customers in more than 115 countries and produced record levels of high-margin recurring airtime contract revenue. Sales at leading e-commerce marketplace sites like Amazon remain strong, which is important as we move into what is traditionally a slower seasonal period. To capitalize on this demand, we are continuing to diversify our global reach. That is why we are pleased to have recently expanded our consumer sales channels through an agreement with Decathlon, the world's largest sporting goods retailer, which has begun selling an array of satellite connectivity products to its online customers in 20 countries. The expansion of our e-commerce network of branded storefronts and marketplaces on major international e-commerce sites and specialized retail destinations like Decathlon furthers our ability to capture an even greater share of global category spending.

David PhippsCEO

We believe that this expanded reach will continue contributing to sustained and predictable growth in this part of our business. We have also expanded onto other leading European marketplaces, including Mountain Warehouse and the newly launched Easy Shop, further increasing our reach to customers who prefer to shop online, with additional marketplaces expected later this year. At this point, I would now like to turn the call over to Birute for her update.

Birute NorkuteVP of Healthcare Operations

Thank you, David. During the third quarter, our healthcare operations continued to deliver significantly stronger profitability compared with the prior year. Our gross margin for the current quarter reached a little over 41%, up from 18% a year earlier, although it declined approximately 5 percentage points sequentially from the prior quarter. A significant contributor to the decline in profitability was the permanent closure of a customer's medication fulfillment facility that we had previously served. Because that business carried particularly strong margins, its loss had a disproportionate impact on our profitability. Turning to retail, prescription volumes remained below prior year levels, reflecting changes in payer mix and shifts in our customer relationships. We fulfill prescriptions for numerous healthcare clinics and continue establishing new partnerships. However, as some clinics grow, they choose to establish their own pharmacies, bringing prescription fulfillment in-house.

Birute NorkuteVP of Healthcare Operations

This contributes to fluctuations in our retail volumes and reinforces the importance of continually developing new customer relationships. It is also why we are looking into novel services, such as automated dispensing at the point of care, something we believe will not only strengthen our relationships with existing customers, but also differentiate us from our competitors and help attract new customers. Medicare's Maximum Fair Price program has also affected prescription economics compared with 2025, although we did not experience a significant additional impact during the third quarter. Meanwhile, long-term care prescription volumes remain stable, while our 340B volumes continue to grow as previously contracted covered entities became operational. The quarterly HRSA registration process creates a natural delay between signing new agreements and generating prescription revenue.

Birute NorkuteVP of Healthcare Operations

These market conditions reinforce the importance of diversifying our healthcare business across multiple revenue streams and patient populations, an approach central to our healthcare growth plans. As David mentioned, our expansion into Pensacola and Jacksonville supports this strategy, providing opportunities to grow retail prescriptions while introducing additional pharmacy services to new healthcare partners. As we previously announced, we are also advancing our automated prescription dispensing initiative with our first point-of-care kiosk currently on its way for installation. In parallel, we are developing new partnership opportunities involving innovative medication management, customized packaging, and home delivery solutions designed to improve medication adherence while creating additional recurring retail prescription revenue opportunities. Across our pharmacy network, our priorities remain disciplined purchasing, effective inventory management, and operational efficiency as we continue building a more diversified and sustainable healthcare business. That concludes my remarks. Back to you, David.

David PhippsCEO

Thank you, Biruta. At this point, I will turn the call over to Amanda to discuss our financial results for the quarter ended September 30, 2026.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day